top of page

Eleftherios Vorrias

Medical Oncologist

Dr. Eleftherios Vorrias is a Consultant Medical Oncologist with his main areas of interest being thoracic and gastrointestinal malignancies, as well as sarcomas. He was born and raised on the Greek island of Chios, studied Medicine at the Aristotle University of Thessaloniki and completed his residency in Medical Oncology at the University Clinic of the Crete University, where he also is a PhD candidate.


He is specialized in administering systemic treatments for malignant diseases (chemotherapy, immunotherapy, targeted therapies) and also maintaining quality of life and palliative care for oncological patients.

dct-VhrachimisAl.jpg
Education / Academic Experience
  • 2012 – Undergraduate Medical Degree – Aristotle University of Thessaloniki

  • 2012 – Medical Elective – University of Glasgow

  • 2013-2014 – ECFMG USA certification

  • 2014 – Medical Observership – East Carolina University

  • 2015 – Resident of Internal Medicine – Chios General Hospital ‘Skylitsion’

  • 2018 – Resident of Internal Medicine – Heraklion University Hospital

  • 2019 – Resident of Medical Oncology – Heraklion University Hospital

  • 2020 – Initiation of Doctoral Thesis about the prognostic and predictive value of a miRNA signature, for early stage NSCLC after surgery

  • 2022 – Greek Academy of Medical Oncology

Professional Experience
  • 2012 – Army Doctor – 3rd Special Forces Unit

  • 2015 – Resident of Internal Medicine – Chios General Hospital ‘Skylitsion’

  • 2017 – Rural Doctor – Kalimassia rural medical center

  • 2018 – Resident of Internal Medicine – Heraklion University Hospital

  • 2019 – Resident of Haematology – Heraklion University Hospital

  • 2019 – Resident of Medical Oncology – Heraklion University Hospital

  • 2023 – Consultant of Medical Oncology – German Medical Institute

Certifications / Courses
  • ECFMG certified

  • ACLS / BLS certified

  • Greek Academy of Medical Oncology

Publications
  1. Prognostic role of immune checkpoints mRNA expression in peripheral blood of non-small cell lung cancer patients treated with immune checkpoint inhibitors (2022) – Annals of Oncology, doi:10.1016/j.annonc.2022.07.1198 

  2. Monitoring of PD-L1 expression on circulating immune cells of patients with small cell lung cancer (SCLC) receiving first line treatment: Prognostic implications (2022) – Annals of Oncology, doi: 10.1016/j.annonc.2022.02.181 

  3. Assessment of PD-L1 expression on circulating tumor cells (CTCs) and immune cells in peripheral blood of patients with small cell lung cancer (SCLC) (2021) – Annals of Oncology, doi: 10.1016/j.annonc.2021.08.237 

  4. Intrameningioma metastasis: A case-based literature review (2021) – J Clin Neurosci., doi: 10.1016/j.jocn.2021.08.028 

  5. MicroRNA expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer (2021) – The 1st Electronic Conference on Cancers, Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, doi: 10.3390/IECC2021-09206 

  6. Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer (2020) – Cells (9), doi: 10.3390/cells9112514

Professional Memberships

Member of:

  • ESMO

  • ASCO

  • EOPE

  • EOSSO

  • EMKAPES


bottom of page